The Journal of Clinical Investigation family of journals To view or add a comment, sign in Retatrutide (LY-3437943) is a next-generation triple incretin receptor agonist that simultaneously activates the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
Insurers and policymakers arent just asking, Is this a good treatment? Kim said
These countries have a comparatively lower OOP exposure: Turkey has restrictions on the online purchasing of semaglutide, reducing accessibility, and Saudi Arabia has online channels but a focus on state-provisioned healthcare over OOP payments signals their cultural, and structural propensity to rely less on the private market
The cheapest option is only a good deal if the medication is properly compounded, the provider oversight is adequate, and the company operates transparently
My advice is to look up the pharmacies that Eden uses
In the SURMOUNT-1 clinical trial, participants on the highest dose of Mounjaro (15 mg) lost an average of 22.5% of their body weight over 72 weeks 1